Thea Bätz provides an overview of systemic treatment options for patients with advanced hepatocellular carcinoma (HCC)
Thea Bätz provides an overview of systemic treatment options for patients with advanced hepatocellular carcinoma (HCC)
Thea Bätz works as study coordinator in the outpatient department for hepatocellular carcinomas at the Johannes Gutenberg University in Mainz. In this function, she cares for study patients and outpatients. After completing her training, she worked for 18 years as a children’s nurse at the University Hospital in Lübeck. Since 2000 Thea Bätz has been working at the University Medical Center Mainz, where she first worked in cardiology and GI oncology. She completed her training as a study assistant and has been working in the HCC area since the SHARP Trial. Due to the close cooperation within the study office she is also involved in the GI oncology area. In recent years, she has participated in several projects on practical work with oncological patients, taking into consideration international differences.
Optimising treatment strategies and AE management
Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer
An overview of the EMERALD subgroup analyses
A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC
Survey findings presented at ONS 2025 and published in the journal Healthcare